Obtenga las últimas noticias sobre las acciones de Regenxbio con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de RGNX

Últimas noticias sobre

REGENXBIO INC

Regenxbio

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Movers_Stocks

AAOI

AFYA

AKBA

BTBT

CVNA

DOCU

FUTU

GDOT

QBTS

RBRK

RDUS

RGNX

RGTI

SMTC

SOUN

ULTA

Semtech sorprendió al mercado con ingresos y ganancias superiores a lo esperado. Inversores reaccionan ante este sólido desempeño trimestral.

Semtech, Rubrik, DocuSign, PagerDuty y otras acciones estadounidenses que suben el viernes

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEHR

ATCH

ATPC

AVGR

CANG

CHCI

HCWC

LIDR

NMHI

PHIO

PIII

RIME

SANG

STAF

URGN

YOSH

Las acciones de KB Home suben 9,1% tras superar expectativas de ganancias. Descubre los mayores ganadores y perdedores del mercado hoy.

Las acciones de KB Home se disparan un 9%; 20 acciones que se mueven en el premercado de EE.UU.

Regenxbio Inc

Press Releases

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

Earnings

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

Small Cap

REGENXBIO Announces Presentation at the World Muscle Society

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

Absci

ADC Therapeutics

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

CytomX Therapeutics

Emergent BioSolutions

Erasca

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

I-MAB

Inventiva S.A. - American Depository Shares

Inventiva

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals

Kodiak Sciences

Keros Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

MeiraGTx Hldgs

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Monopar Therapeutics

Organogenesis Holdings

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Savara

Verastem

HC Wainwright & Co.

Chardan Capital

RBC Capital

Barclays

Goldman Sachs

Comments

Regenxbio Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL